Display options
Cite
Yeh E, Brown G. Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers. Can J Hosp Pharm. 2009;62(6):457-63doi: 10.4212/cjhp.v62i6.843.
Yeh, E., & Brown, G. (2009). Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers. The Canadian journal of hospital pharmacy, 62(6), 457-63. https://doi.org/10.4212/cjhp.v62i6.843
Yeh, Eugenia, and Brown, Glen. "Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers." The Canadian journal of hospital pharmacy vol. 62,6 (2009): 457-63. doi: https://doi.org/10.4212/cjhp.v62i6.843
Yeh E, Brown G. Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers. Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843. PMID: 22478933; PMCID: PMC2827012.
Copy Download .nbib Format: NLM
Share it on

Can J Hosp Pharm. 2009 Nov;62(6):457-63. doi: 10.4212/cjhp.v62i6.843.

Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

The Canadian journal of hospital pharmacy

Eugenia Yeh, Glen Brown

Affiliations

  1. , BSc(Pharm), is with the Pharmacy, St Paul's Hospital, Vancouver, British Columbia.

PMID: 22478933 PMCID: PMC2827012 DOI: 10.4212/cjhp.v62i6.843

Abstract

BACKGROUND: Continuous renal replacement therapy is used to manage fluid and solute imbalances in critically ill patients but may affect the clearance of concurrently administered drugs. The impact of continuous renal replacement therapy on pharmacokinetics has been summarized, but previous reports have included studies involving various modes of therapy, filter membranes, and brands of dialyzers, which makes it difficult to apply the recommendations to individual patients. In Canada, continuous venovenous hemodiafiltration (CVVHDF) with a Prismaflex dialyzer machine (Gambro, Saint-Léonard, Quebec) and AN69 filter membranes is the most common mode of continuous renal replacement therapy for critically ill patients.

OBJECTIVE: To develop a set of dosage recommendations for commonly encountered medications used in treating critically ill patients who are undergoing CVVHDF with a Prismaflex dialyzer and AN69 filter membranes.

METHODS: A literature search was conducted to identify studies of the pharmacokinetics and disposition of drugs in patients undergoing CVVHDF via a Prismaflex dialyzer (sold under 3 brand names: Gambro, Hospal, and Prima) equipped with polyacrylonitrile (AN69) filter membranes. From each study, the mean total clearance of each study medication during CVVHDF was extracted and compared with clearance of the drug in patients not undergoing CVVHDF, to produce dosage guidelines for patients undergoing CVVHDF.

RESULTS: A total of 22 studies of 14 medications were included in the final review. For most of the drugs, the total clearance during CVVHDF was less than clearance in patients whose renal function was presumed to be normal. Fluconazole and moxifloxacin had greater total clearance during CVVHDF, but a dose adjustment during CVVHDF was deemed necessary only for fluconazole.

CONCLUSIONS: Dosing recommendations were created for concurrently administered drugs for patients undergoing treatment with this particular CVVHDF equipment. Patient-specific factors and clinical judgement should also be taken into account.

References

  1. Clin Pharmacokinet. 2006;45(7):649-63 - PubMed
  2. Intensive Care Med. 2007 Apr;33(4):660-6 - PubMed
  3. Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4 - PubMed
  4. J Clin Pharmacol. 1980 Apr;20(4):197-201 - PubMed
  5. Antimicrob Agents Chemother. 1992 Oct;36(10):2085-92 - PubMed
  6. Crit Care Med. 2000 Mar;28(3):632-7 - PubMed
  7. J Antimicrob Chemother. 2004 Jul;54(1):269-70 - PubMed
  8. Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5 - PubMed
  9. Antimicrob Agents Chemother. 1983 Jun;23(6):892-6 - PubMed
  10. Antimicrob Agents Chemother. 1984 Aug;26(2):208-10 - PubMed
  11. JAMA. 1995 Dec 6;274(21):1706-13 - PubMed
  12. J Clin Pharmacol. 2003 Dec;43(12):1329-40 - PubMed
  13. Crit Care. 2006 Feb;10(1):R26 - PubMed
  14. Antimicrob Agents Chemother. 1992 Mar;36(3):552-7 - PubMed
  15. Intensive Care Med. 1999 Jun;25(6):594-8 - PubMed
  16. Clin Ther. 2005 May;27(5):599-608 - PubMed
  17. J Clin Pharmacol. 1990 Oct;30(10):900-10 - PubMed
  18. J Antimicrob Chemother. 2004 Oct;54(4):780-4 - PubMed
  19. Antimicrob Agents Chemother. 2005 Nov;49(11):4814-5 - PubMed
  20. Antimicrob Agents Chemother. 2001 Oct;45(10):2949-54 - PubMed
  21. J Antimicrob Chemother. 2007 Nov;60(5):1085-90 - PubMed
  22. J Antimicrob Chemother. 2003 Dec;52(6):987-92 - PubMed
  23. Eur J Clin Pharmacol. 1979 Nov;16(5):331-4 - PubMed
  24. Intensive Care Med. 2001 Apr;27(4):665-72 - PubMed
  25. Antimicrob Agents Chemother. 1990 Apr;34(4):614-21 - PubMed
  26. Antimicrob Agents Chemother. 1978 Jul;14(1):40-4 - PubMed
  27. Antimicrob Agents Chemother. 1985 Nov;28(5):648-53 - PubMed
  28. Intensive Care Med. 1993;19(6):347-50 - PubMed
  29. J Infect Chemother. 2001 Mar;7(1):1-9 - PubMed
  30. Clin Ther. 1990 May-Jun;12(3):206-15 - PubMed
  31. Antimicrob Agents Chemother. 1992 Jul;36(7):1437-40 - PubMed
  32. Pharmacotherapy. 2002 Feb;22(2):175-83 - PubMed
  33. Antimicrob Agents Chemother. 1984 Nov;26(5):715-21 - PubMed
  34. Chemotherapy. 1993;39(1):6-12 - PubMed
  35. Thromb Haemost. 1995 Apr;73(4):630-40 - PubMed
  36. Eur J Clin Pharmacol. 2000 Dec;56(9-10):671-8 - PubMed
  37. J Clin Pharmacol. 2005 Apr;45(4):477-81 - PubMed
  38. Br J Clin Pharmacol. 2003 Dec;56 Suppl 1:2-9 - PubMed
  39. Chemotherapy. 2007;53(3):194-201 - PubMed
  40. Pharmacotherapy. 2005 Oct;25(10):1310-8 - PubMed
  41. Clin Ther. 2005 Sep;27(9):1444-51 - PubMed
  42. Crit Care Med. 2008 Jan;36(1):296-327 - PubMed
  43. Antimicrob Agents Chemother. 2001 Nov;45(11):3148-55 - PubMed
  44. Clin Nephrol. 2007 May;67(5):267-84 - PubMed
  45. J Clin Pharmacol. 2005 Nov;45(11):1294-304 - PubMed
  46. Br J Clin Pharmacol. 2004 Sep;58(3):259-68 - PubMed
  47. Rev Infect Dis. 1981 Nov-Dec;3 suppl:S230-5 - PubMed
  48. Antimicrob Agents Chemother. 2005 Jun;49(6):2421-8 - PubMed

Publication Types